CHICAGO, Nov. 28, 2011 /PRNewswire via COMTEX/ -- Royal Philips Electronics PHG -0.27% (aex:PHI) is announcing 510(k) clearance from the Food and Drug Administration (FDA) for the company's first commercially available whole body positron emission tomography/magnetic resonance (PET/MR) imaging system, the Ingenuity TF PET/MR. This leading edge platform will redefine how medicine is practiced in the future by helping clinicians and researchers investigate novel personalized medicine and treatments for oncology, cardiology and neurology. The system is on display at the 97th annual meeting of the Radiological Society of North America (RSNA), November 27 - December 2.
It was previously thought that PET and MR scans were incompatible; however, Philips overcame the enormous technical hurdles, through advances in technology, to create a new class of hybrid imaging that will push the bounds of what's possible in imaging. The system is designed to provide a state-of-the-art platform well into the future by facilitating the addition of new technologies as they become available.
The Ingenuity TF PET/MR delivers increased economic value, as it is a sequential imaging system that has a similar clinical workflow experience to PET/CT, the current benchmark for hybrid imaging. In addition, the system is designed so the patient table rotates between each modality to scan a patient, thus enabling the system to perform both standalone MR and hybrid PET/MR studies.
source: MarketWatch
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment